Processa CFO buys 2,654 shares at $2.22

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. On this transaction date, he bought 2,654 shares of common stock at a price of $2.22 per share. Following the purchase, his direct holdings increased to 13,412 shares of common stock.

Insider Trade Summary

Net Buyer: 2,654 shares

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 2,654 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,654	$2.22	$6K

Holdings After Transaction: Common Stock — 13,412 shares (Direct)

Key Figures

Shares purchased: 2,654 shares Purchase price: $2.22 per share Shares held after transaction: 13,412 shares +2 more

5 metrics

Shares purchased 2,654 shares Open-market purchase of common stock

Purchase price $2.22 per share Transaction price for the acquired shares

Shares held after transaction 13,412 shares Direct holdings following the purchase

Transaction code P Purchase in open market or private transaction

Net buy shares 2,654 shares Net change in common stock position from this filing

Key Terms

open-market purchase, non-derivative, direct ownership, transaction code "P"

4 terms

open-market purchase financial

"The action is described as an open-market purchase of 2,654 shares."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

"The transaction is categorized as a non-derivative acquisition of common stock."

direct ownership financial

"The filing classifies the 13,412 shares after the transaction as direct ownership."

transaction code "P" regulatory

"The Form 4 uses transaction code "P" for this purchase."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Processa Pharmaceuticals (PCSA) report on this Form 4?

Processa Pharmaceuticals reported that its Chief Financial Officer, Russell Skibsted, completed an open-market purchase of 2,654 shares of common stock at $2.22 per share. The transaction is categorized as a non-derivative acquisition of common stock.

How many Processa Pharmaceuticals (PCSA) shares did the CFO hold after the reported trade?

After the reported open-market purchase, Chief Financial Officer Russell Skibsted directly held 13,412 shares of Processa Pharmaceuticals common stock. This total reflects his position immediately following the acquisition of 2,654 additional shares on the transaction date.

Was the Processa Pharmaceuticals (PCSA) CFO trade a buy or a sell?

The trade was a buy. The Form 4 shows a transaction code “P” and describes the action as an open-market purchase of 2,654 shares of Processa Pharmaceuticals common stock at $2.22 per share by the Chief Financial Officer.

What price did the Processa Pharmaceuticals (PCSA) CFO pay per share in the transaction?

The Chief Financial Officer paid $2.22 per share for Processa Pharmaceuticals common stock in this transaction. The Form 4 identifies this as the transaction price for the 2,654 shares acquired in the open-market purchase on the reported date.

Is the Processa Pharmaceuticals (PCSA) CFO ownership classified as direct or indirect after this Form 4?

The ownership is classified as direct. The Form 4 lists the transaction as non-derivative common stock with a direct ownership code, and the 13,412 shares shown after the transaction are held directly by the Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		P		2,654	A	$2.22	13,412	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)